We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

52 hedge funds and large institutions have $127M invested in VistaGen Therapeutics in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,238% more capital invested

Capital invested by funds: $2.39M → $127M (+$125M)

600% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

86% more funds holding

Funds holding: 28 → 52 (+24)

1.48% more ownership

Funds ownership: 0.15% → 1.63% (+1.5%)

Holders
52
Holders Change
+24
Holders Change %
+85.71%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
8
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$7.96M
2
VA
VR Adviser
New York
+$7.96M
3
ACP
Acuta Capital Partners
California
+$6.38M
4
O
OrbiMed
New York
+$6.38M
5
Franklin Resources
Franklin Resources
California
+$5.31M

Top Sellers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
-$92K
2
Goldman Sachs
Goldman Sachs
New York
-$48.6K
3
LPL Financial
LPL Financial
California
-$21.3K
4
RC
RBF Capital
California
-$17K
5
TRCT
Tower Research Capital (TRC)
New York
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$18.2M +$7.96M +312,000 New
VA
2
VR Adviser
New York
$18.2M +$7.96M +312,000 New
ACP
3
Acuta Capital Partners
California
$14.6M +$6.38M +250,000 New
O
4
OrbiMed
New York
$14.6M +$6.38M +250,000 New
Franklin Resources
5
Franklin Resources
California
$12.1M +$5.31M +208,013 New
IC
6
Ikarian Capital
Texas
$8.7M +$3.82M +149,532 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.33M +$1.12M +43,852 +68%
CC
8
Commodore Capital
New York
$6.11M +$2.68M +105,000 New
SFM
9
Sphera Funds Management
Israel
$5.29M +$2.32M +90,833 New
GTC
10
Ghost Tree Capital
New York
$4.73M +$2.08M +81,333 New
ACM
11
Asymmetry Capital Management
California
$4.34M +$1.91M +74,660 New
PVI
12
Pura Vida Investments
New York
$2.83M +$1.24M +48,611 New
GPCM
13
Granite Point Capital Management
Massachusetts
$1.88M +$825K +32,333 New
Renaissance Technologies
14
Renaissance Technologies
New York
$1.62M +$605K +23,700 +573%
Millennium Management
15
Millennium Management
New York
$1.52M +$665K +26,056 New
SCM
16
Stonepine Capital Management
Oregon
$970K +$425K +16,667 New
BFM
17
Boothbay Fund Management
New York
$907K +$398K +15,581 New
MIM
18
Monashee Investment Management
Massachusetts
$566K +$248K +9,722 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$558K +$30.9K +1,212 +14%
ECM
20
ExodusPoint Capital Management
New York
$448K +$197K +7,701 New
Osaic Holdings
21
Osaic Holdings
Arizona
$333K – – –
PCM
22
Prelude Capital Management
New York
$292K +$128K +5,012 New
Two Sigma Investments
23
Two Sigma Investments
New York
$275K +$104K +4,080 +641%
DADC
24
D.A. Davidson & Co
Montana
$267K – – –
Two Sigma Advisers
25
Two Sigma Advisers
New York
$230K +$76.1K +2,983 +311%
1
2 3

VTGN Hedge Fund Activity: Q4 2020 in Review

52 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2020, worth a combined $127M — up 5,238% from $2.39M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VTGN positions and 4 closed out — a net gain of 24 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $7.96M. The largest seller was HighTower Advisors, exiting entirely with an estimated $92K sold.

  • 52 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2020, up from 28 in Q3 2020.
  • Funds reported $127M of VistaGen Therapeutics stock for Q4 2020, up 5,238% quarter-over-quarter.
  • 28 funds opened new VistaGen Therapeutics positions in Q4 2020 and 4 closed out, a net change of +24 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2020 was NEA Management Company, an estimated $7.96M added.
  • The largest VistaGen Therapeutics seller in Q4 2020 was HighTower Advisors, an estimated $92K sold.

Based on aggregated 13F filings for Q4 2020.